Status:
COMPLETED
Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)
Lead Sponsor:
University Hospital, Ghent
Conditions:
Infection With Human Papillomavirus
Eligibility:
FEMALE
9-13 years
Phase:
PHASE4
Brief Summary
Six identical female twins aged 9-13 years will participate. One sib of each twin pair will be given Cervarix according to the 0, 1, 6 month vaccination scheme, while the other sib will be given Garda...
Eligibility Criteria
Inclusion
- Six homozygous twins in good health, without preceding sexual activity (virgin). Subjects have a negative pregnancy test on the day of vaccination and have agreed to continue abstinence during the entire study period and for two months after completion of the vaccination series.
Exclusion
- Subjects are not participating in any other clinical trials and have not been vaccinated previously against HPV and have not had an administration of MPL or AS04 in the past.
Key Trial Info
Start Date :
June 25 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 23 2015
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01914367
Start Date
June 25 2013
End Date
September 23 2015
Last Update
December 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ghent University Hospital
Ghent, Oost-Vlaanderen, Belgium, 9000